BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Mar 19, 2021
Product Development

Self-amplifying may be the next frontier in RNA therapies

With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s...
BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the ninth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

Alzheimer’s disease immunotherapy reduces β-amyloid without increasing brain bleedingPublished in Science Translational Medicine, Denali Therapeutics Inc. (NASDAQ:DNLI) and Washington University School of Medicine in St. Louis researchers led by David Holtzman found that an anti-APOE...
BioCentury | Feb 19, 2021
Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes. Primmune Therapeutics Inc. President, Chairman and CEO Charles McDermott told BioCentury, “The TLR7 receptor is your body’s most upstream receptor for...
BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | Feb 5, 2021
Emerging Company Profile

Apros: Engineering tissue-targeted TLR agonists

Apros is developing a suite of tissue-targeted TLR7 agonists for indications ranging from cancer to infectious disease that aim to avoid systemic toxicities that have plagued the drug class.  Lead candidate APR003, a TLR7 agonist...
Items per page:
1 - 10 of 1288